StemRIM Public

StemRIM is a biotechnology company focused on developing "regeneration-inducing medicines". Their main goal is to develop drugs that mobilize stem cells in the body to injured or diseased tissue, promoting functional tissue regeneration. StemRIM's approach involves increasing the supply of stem cells in the body without removing them, and inducing their migration to damaged tissue. This innovative mechanism of action has the potential to revolutionize regenerative medicine. StemRIM's achievements include the development of a regenerative medicine that increases the amount of mesenchymal stem cells in the body, accelerating the reconstruction of damaged tissue. They are also working on gene therapy techniques to treat severe genetic diseases by editing and reintroducing the patient's own stem cells.

Investors

Technology: Regenerative Medicine
Headquarters: Japan
Funding Status: IPO
Founded Date: 2006-10-30
Last Funding Type: Venture - Series Unknown
Investors Number: 11
Last Funding Date: 43462
Estimated Revenue: $1M to $10M
Employee Number: 12K
Total Funding: 3449775000
Industry: Stem Cells (Regenerative Medicine)
Investor Type: For Profit
Register and Claim Ownership